Cambridge Healthtech Institute’s 11th Annual

Engineering Bispecific Antibodies

Designing New Off-the-Shelf Antibody Therapies

May 7-8, 2020

The universe of bispecific antibody platforms, combinations, strategies and chemistry is growing exponentially and the application of bispecific constructs in immunotherapy is proving to be an extremely effective combination. Fine tuning specificity, calibrating potency while minimizing safety risk are all top priorities of antibody engineers for targets in oncology, immuno-oncology and infectious disease. Early results with new platforms and evolving techniques will be shared. Plan to take part in the premier event in the bispecific antibody community and learn what is next for tackling the biggest challenges facing the field and how to overcome them.

Preliminary Agenda

BISPECIFIC CO-STIMULATORY COMBINATIONS

KEYNOTE PRESENTATION: Providing 4-1BB Co-Stimulation to T Cells for Off-the-Shelf Combination Cancer Immunotherapy

Christian Klein, PhD, Head, Oncology Programs & Department Head Cancer Immunotherapy Discovery 3, Roche Innovation Center Zurich, Roche Pharma Research & Early Development

Simultaneous Multiple Interaction T Cell Engagers (SMITEs): Improving Bispecific Therapies through T Cell Costimulation

Colin E. Correnti, PhD, Senior Scientist and Director of Protein Sciences, Fred Hutchinson Cancer Research Center

Co-Stimulatory Bispecific Antibodies for Combination Cancer Immunotherapy

Dimitris Skokos, PhD, Director, Immune & Inflammatory Diseases, Regeneron Pharmaceuticals, Inc.

T-Cell Engaging Bispecific Antibodies: Comparing Pfizer’s Platforms

Javier Chaparro-Riggers, PhD, Executive Director, Biomedicine Design, Pfizer

MULTISPECIFICITY AND COMBINATION STRATEGIES

Rational Combinatorial CAR Designs for Effective Immunotherapy

Mohamad Hamieh, PhD, Research Associate, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center

Novel Insights into Immune Cell-Mediated Killing of Tumor Cells

Stephen J. Demarest, PhD, Senior Research Fellow, Eli Lilly

LUNCHEON PRESENTATION: Unique in vitro Technologies for R&D of Biologics Including scFv, Fab, IgG, Cyclic Peptide and Bispecific

Takashi Ebihara, PhD, COO, GeneFrontier Corporation

CLINICAL VALIDATION OF PLATFORMS

KEYNOTE PRESENTATION: Trends in Bispecific Antibody Development

Janice M. Reichert, PhD, Executive Director, The Antibody Society

Talk Title to be Announced

Tariq Ghayur, PhD, Distinguished Research Fellow, AbbVie Bioresearch Center

T Cell Therapeutics to Address Hematological Malignancies and Solid Tumors

Tara Arvedson, PhD, Executive Director, Oncology and Inflammation Research, Amgen

TUNING SPECIFICITY – BALANCING POTENCY VS. SIDE-EFFECTS

Immunological Synapses in Human Health and Disease

Salvatore Valitutti, MD, Director, Research, INSERM; Head, Laboratory Molecular Dynamics of Lymphocyte Interactions, Cancer Research Center of Toulouse

A Novel Bispecific Antibody Platform that Elicits Efficient Tumor Lysis with Minimal Cytokine Release in Liquid and Solid Tumors

Nathan Trinklein, PhD, CTO, Discovery, Teneobio

Optimizing Cytolytic Activity and Cytokine Release via Affinity Modulation of CD3-Engaging DART® Molecules for Redirected T Cell Killing

Gundo Diedrich, PhD, Director, Antibody Engineering, MacroGenics, Inc.

Activating and Recruiting T Cells with Bispecific Antibodies and Potency-Optimized Cytokines

John Desjarlais, PhD, CSO, Xencor

* The program is subject to change without notice, due to unforeseen reason.